Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.
Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.
In this video Marc discusses:
Note: This interview was filmed on 22 March 2022.